StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

Myriad Genetics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Myriad Genetics's EV/EBITDA was 28.3× on Apr 30, 2020, against 23.4× a year earlier. Over the last 5 years it ranged from 6.7× to 36.6×, with a median of 15.8×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2020Apr 30, 202028.3×−7.8
2019Dec 31, 201936.1×+13.1
2018Dec 31, 201823.0×+10.4
2017Dec 29, 201712.5×+4.4
2016Dec 30, 20168.1×−7.9
2015Dec 31, 201516.1×+6.2
2014Dec 31, 20149.9×+5.3
2013Dec 31, 20134.6×−4.9
2012Dec 31, 20129.5×+1.2
2011Dec 30, 20118.3×−3.1
2010Dec 31, 201011.4×−7.1
2009Dec 31, 200918.5×–

More Myriad Genetics figures

See a number that looks wrong?